Glucobay® – the most extensively investigated and widely prescribed α-glucosidase inhibitor – reduces post prandial plasma glucose excursions by delaying the absorption of carbohydrate from the small intestine. Glucobay® is an effective first-line therapy for patients with newly diagnosed type 2 diabetes, and induces a further improvement in glycemic control when used in combination with other antidiabetes agents.